A biosimilar of infliximab appeared to perform as well as the originator drug for the treatment of inflammatory bowel disease, according to interim results from an ongoing multicenter, randomized controlled, double-blind trial in the Netherlands.
The team enrolled 47 men and women with IBD (35 with Crohn’s disease; 12 with ulcerative colitis). All patients were in clinical and biochemical remission on long-term use of infliximab (Remicade, Janssen), and all were randomly assigned either to